2026-10-25
Does not pass
Doximity, does not pass the ethical screen. The binding factor is interest/revenue 5.5%.
NAS100 26,906 −5.38%
S&P 7,400 −3.75%
GOLD $4,127 +1.33%
BTC $76,159 −5.28%
VIX 24.13 +45.27%
latest tape · as of 20:03 UTC
The Screen · Healthcare · Health Information Services
Doximity, Inc.
DOCS · the NYSE · USD · Market cap $5.9B
Doximity, Inc.
FAIL · Does not pass the screen34.67 USD
Price as of 4 Nov 2026Daily close, not a live quote
Screened 2026-11-04 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price34.67 USD at the 4 Nov 2026 close
- Our value readFair vs our fair value, as of 4 Nov 2026
- Our regime readAccumulation, as of 4 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.16)
- Last reviewed4 Nov 2026 (1 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
PRICE · ONE YEAR
Our fair-value range: $25.71 to $42.85, base estimate $31.89 (screen dated 2026-11-04).
- Trend Accumulation
- Insiders insiders sold, $80,167, latest filing 2026-10-14
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.16, read 2026-11-04
- Ethical does not pass the values gate
Price34.67 USD
Fair value31.89
Ethical score93.6/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-10-11Read Accumulation26.57+30.5% to today ✓Markdown gives way to Accumulation first Accumulation read since July
2026-10-02Read Markdown26.57+30.5% to today Markup gives way to Markdown after a 7% rise in 5 weeks
2026-08-27Read Markup24.94+39.0% to today ✓Accumulation gives way to Markup after a 16% rise in 5 weeks
2026-07-26Read Accumulation21.52+61.1% to today ✓Distribution gives way to Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its accumulation label.
Doximity, Inc. holds its Accumulation at $34.67. Consolidating, no directional conviction, held for 38 days.
| Phase | Accumulation |
| Quantitative state | Consolidating, no directional conviction, held for 38 days |
| Price at the screen | $34.67 |
| Valuation | 39.11 trailing · 21.33 forward price to earnings |
| Values screen | FAIL · score 93.6 |
| Beta | 1.22 |
Five Screens, Shown in Full
Does not pass. Interest/revenue 5.5%
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 0.24% | Below 33% | Interest-bearing debt is just 0.2% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 16.76% | Below 33% | Cash held in interest-bearing accounts and securities is 16.8% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
| Revenue purity | 5.54% | Below 5% | 5.5% of revenue comes from non-compliant sources, over the 5% line. | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Doximity, does not pass the ethical screen. The binding factor is interest/revenue 5.5%.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Doximity, clears all five screens. Its business is in a permissible area, its debt is near-nil, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
Follow this verdict
Get an email when DOCS's ethical verdict changes
Today DOCS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 4 Nov 2026: it trades above our $31.89 fair value estimate, strong competitive moat, 7.30% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 8.7% above the base estimate.
Third-party analyst targets: 18 covering, consensus Hold. The average target sits −15% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & ProjectionsWhere our models see it going: fair-value estimate $31.89, with a range of $25.71 to $42.85, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsWhy it is worth knowing
A quality business: a strong moat and 25% profit margins. At the screened price it sits 2% above our $31.89 fair value: priced for the quality, not a bargain.
| Forward P/E | 21.3xexpensive even after accounting for its growth |
| Trailing P/E | 39.1xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 0.85 |
| EPS, forward | 1.56 |
| Revenue growth | +7.3%slow but positive growth |
| Profit margin | 25.5%healthy profit margins |
| Return on equity | 17.2%a solid return on shareholder capital |
| FCF yield | 4.05% |
| Debt to equity | 1.06a meaningful debt load worth watching |
| Current ratio | 6.08comfortably covers its short-term bills |
| Beta | 1.22moves a little more than the market |
| Short interest, float | 0.09% |
| 52-week range | 17.15 - 69.00 |
| Moat | STRONG |
| Market cap | $5.9B |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Titan Case StudyOur full written analysis of DOCS: DOCS Case Study → 2026-07-02
Where & How to TradeDOCS trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-11-05
Accumulation $34.67
+6.3% Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (18 analysts) rates it hold, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-04
Accumulation $32.60
-0.5% Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (18 analysts) rates it hold, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03
Accumulation $32.76
+0.0% Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (18 analysts) rates it hold, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02
Accumulation $32.76
+0.0% Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (18 analysts) rates it hold, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01
Accumulation $32.76
-2.6% Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (18 analysts) rates it hold, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31
Accumulation $33.63
+0.0% Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (18 analysts) rates it hold, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30
Accumulation $33.63
+1.2% Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (18 analysts) rates it hold, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29
Accumulation $33.24
+5.5% Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (18 analysts) rates it hold, with a mean price target of $31. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25
Accumulation $31.50
+0.0% Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading overbought. Over the past year the shares are down 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (18 analysts) rates it hold, with a mean price target of $31.
2026-10-18
Accumulation $31.50
+18.6% Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 18.6% since our last review. Ethical screening: PASS with near-perfect ethical score. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading oversold. Over the past year the shares are down 65%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (18 analysts) rates it hold, with a mean price target of $30.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- TEM vs. DOCS: Which Medical Info Systems Stock Is the Better Pick Now? Yahoo Finance · 6d ago
- Doximity (DOCS) Registers a Bigger Fall Than the Market: Important Facts to Note Yahoo Finance · 7d ago
- Doximity Launches DoseCheck to Catch Dangerous AI Drug Dosing Errors Before They Reach Doctors Yahoo Finance · 7d ago
- Can Wolters Kluwer (ENXTAM:WKL) Keep Looking Cheap On Earnings? Yahoo Finance · 7d ago
- Doximity (DOCS) Stock Gets Fair Value Bump As Analysts Split On AI And Margins Yahoo Finance · 15d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
WAYWaystar Holding Corp.
HTFLHeartflow, Inc.
HNGEHinge Health, Inc.
TXG10x Genomics, Inc.
PRVAPrivia Health Group, Inc.
TEMTempus AI, Inc.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-14 | Sitaram Siddharth | Chief Accounting Officer | S - Sale+OE | 2,613 | $80,167 |
| 2026-05-15 | TANGNEY JEFFREY A. | Chief Executive Officer | 322,614 | · | |
| 2026-05-11 | SITARAM SIDDHARTH | Chief Financial Officer | 2,309 | $59,503 | |
| 2026-05-11 | SITARAM SIDDHARTH | Chief Financial Officer | 5,000 | · | |
| 2026-05-07 | WAMPLER KIRA SCHERER | Director | 9,000 | $234,540 | |
| 2026-05-07 | WAMPLER KIRA SCHERER | Director | 9,000 | · | |
| 2026-04-10 | SITARAM SIDDHARTH | Chief Financial Officer | 2,427 | $51,185 | |
| 2026-04-10 | SITARAM SIDDHARTH | Chief Financial Officer | 5,000 | · | |
| 2026-03-10 | SITARAM SIDDHARTH | Chief Financial Officer | 2,319 | $58,833 | |
| 2026-03-10 | SITARAM SIDDHARTH | Chief Financial Officer | 5,000 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $26.26 | -22.7% | · | $773 | -22.7% |
| 2 months | $21.05 | -3.6% | · | $964 | -3.6% |
| 3 months | $24.28 | -16.4% | · | $836 | -16.4% |
| 6 months | $44.13 | -54.0% | · | $460 | -54.0% |
| 1 year | $58.54 | -65.3% | · | $347 | -65.3% |
| 2 years | $29.56 | -31.3% | · | $687 | -31.3% |
| 3 years | $31.67 | -35.9% | · | $641 | -35.9% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever DOCS does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.